All News
RheumNow’s expanded coverage of the #ACR22 meeting is sponsored in part by Bristol-Myers Squibb. All content chosen by RheumNow & its Faculty
Dr. John Cush RheumNow ( View Tweet)
Park et al. Risk-benefit of PJP propylaxis in rituximab treated patients. NNH 86 . NNT - all RTX 146, RTX+high dose steroid 21. This mirrors my practice @RheumNow #ACR22 Abstr#0720 https://t.co/JPtPCqah9R https://t.co/bonRzWFbVw
Richard Conway RichardPAConway ( View Tweet)
Kaneko et al. Tocilizumab leads to significantly lower steroid doses in Adult onset Stills Disease @RheumNow #ACR22 Abstr#0826 https://t.co/jc1S6sdfkm https://t.co/z0cHB4wYu6
Richard Conway RichardPAConway ( View Tweet)
What neonatal factors could affect development into axSpA? Turns out antibiotic exposure (6.2x more likely).
Mode of delivery, early diet (milk vs. formula), maternal smoking (!!) did not show association.
@RheumNow #ACR22 Abs#0868
#ACRBest https://t.co/roCAj5YsCt
Robert B Chao, MD doctorRBC ( View Tweet)
In non-renal SLE, BEL associated w/ a lower risk of severe infection and hospitalizations due to severe infection compared to MTX, AZA, MMF. Abs 0349 #ACR22 @RheumNow https://t.co/0EBpCMPOqF https://t.co/vdxKVJSaZA
Dr. Rachel Tate uptoTate ( View Tweet)
Isenberg et al. Atacicept 150mg in SLE. Reduced flare 36% vs 53%, delayed time to first flare, stabalised renal function (vs decline in PBO), less steroid increase (14% vs 36%), UPCR declined (vs increase in PBO) @RheumNow #ACR22 Abstr#1001 https://t.co/FRWcTAgCrn https://t.co/Amkg84OX2x
Richard Conway RichardPAConway ( View Tweet)
🔥Ignite Talk 10:20AM South Philly Stage🔥 abstract #0946
SLE, birth control, & pregnancy planning
🔥30% of women used no birth control despite only 17% voicing interest in pregnancy
🔥More 1/2 of women interested in pregnancy were not medically ready
#ACR22 @RheumNow
Catherine Sims, MD DrCassySims ( View Tweet)
Vilas-Boas et al. Anti-NOR antibodies. 27.5% of anti-NOR+ diagnosed with rheumatic disease - SSc and UCTD most common. @RheumNow #ACR22 Abstr#0832 https://t.co/OU2hFn3ioK https://t.co/Ve0Jbexycm
Richard Conway RichardPAConway ( View Tweet)
Kahlenberg @Kahlenberglab et al. TYK2i deucravacitinib in SLE. Clinical efficacy (figure). Deucravacitinib suppressed IFN production, IFN-responsive gene expression, IFN-inducible proteins, B cell markers,serological biomarkers. @RheumNow #ACR22 Abstr#1000 https://t.co/zzkoPLOlSR https://t.co/znyG8N5pJ2
Richard Conway RichardPAConway ( View Tweet)
Johnson et al TYK2i deucravacitinib does not inhibit haematologic pathways, Treg function, or IL-15 dependent NK cell function, that JAKi do. @rheumnow #ACR22 Abstr#0584 https://t.co/UTHzUjGmJN https://t.co/NUKKAv3tAr
Richard Conway RichardPAConway ( View Tweet)
Severe non-adherence to HCQ independently assoc'd w/ risk of SLE flare in the following year, with early damage, and 5-year mortality. Abs 0343 #ACR22 @RheumNow https://t.co/JYRWD5QIlf https://t.co/UCWYrHIc4b
Dr. Rachel Tate uptoTate ( View Tweet)
Gopal et al. Withdrawal of immunosuppressants non-inferior to steroid withdrawal in SLE in clinical remission. Numerically higher flare rate in steroid withdrawal group 15 vs 7 (RR 2.1). @RheumNow #ACR22 Abstr#0997 https://t.co/psoHvg0pVG https://t.co/GlsDjpgXGo
Richard Conway RichardPAConway ( View Tweet)
Giblon et al. Incidence depression and anxiety in RA over 30 years. No change in depression, significant increase in anxiety @RheumNow #ACR22 Abstr#0886 https://t.co/1a3sayBEnl https://t.co/jflc3UTbIh
Richard Conway RichardPAConway ( View Tweet)
Bui et al. Outcomes in Adult onset Stills Disease. >40% required ICU admission and 3.5% died in this retrospective study. No effect of concomittent pneumonia. @RheumNow #ACR22 Abstr#0829 https://t.co/YxkXJJ7EGR https://t.co/mMbQ14iRL1
Richard Conway RichardPAConway ( View Tweet)
Madan et al. Ferritin levels more than 7511 and ferritin/ CRP levels more than 204.5 was associated with higher mortality in Macrophage Activation Syndrome @RheumNow #ACR22 Abstr#0825 https://t.co/jL58oCCEWa https://t.co/9V4PW49EyC
Richard Conway RichardPAConway ( View Tweet)
Ma et al. Calprotectin differentiates remission and low disease activity in RA. @RheumNow #ACR22 Abstr#0884 https://t.co/z9oeKPLq5z https://t.co/YFkIBEqT0c
Richard Conway RichardPAConway ( View Tweet)
Sarilumab in GC resistant PMR
🔥SAPHYR🔥
👉Arm 1- sar 200mg Q2W + 14wk GC
👉 Arm 2- PBO Q2W + 52wk GC
🌟RESULTS🌟
💪🏻 Arm 1 - PMR symp + signs ⬇️ wk 2 with continued improvement until wk 52
🌟Arm 1- ⬇️ chance flare post achieving remission
#ACR22 @RheumNow https://t.co/tXQuuoAelP
Patricia Harkins DrTrishHarkins ( View Tweet)
CLE to SLE transition occurred more frequently in pts aged 40 and younger, w/in the first 10 years of dx, and those with SCLE. Abs 0338 #ACR22 @RheumNow https://t.co/XxHjkNL5Hf https://t.co/1WtgmVM7Iz
Dr. Rachel Tate uptoTate ( View Tweet)
Saxena et al Zetomipzomib, a selective immunoproteasome inhibitor in lupus nephritis. Phase 2 study. UPCR=<0.5 achieved 64.7% week 37, pred=<10mg/day 82.4% week 13. @RheumNow #ACR22 Abstr#0992 https://t.co/askpmqsYYG https://t.co/cKoR0bgtWt
Richard Conway RichardPAConway ( View Tweet)
Wallace @zach_wallace_md et al. IgG4-RD in USA. Incidence 1.2/100,000, prevalence 2.8/100,000. Pancreas (43.0%), biliary tract (30.6%), salivary glands (11.7%), retroperitoneum (5.0%). HR 2.51 for mortality in IgG4-RD. @RheumNow #ACR22 Abstr#0713 https://t.co/IpjSKxmHQN
Richard Conway RichardPAConway ( View Tweet)